Analysis of the most common adverse reactions during treatment with Roprostim (Huierning)

Romiplostim is a recombinant thrombopoietin receptor agonist (TPO-RA) mainly used to treat adults and children with chronic immune thrombocytopenia (ITP). It stimulates bone marrow megakaryocyte differentiation and proliferation by simulating the effect of endogenous thrombopoietin (TPO), thereby increasing platelet count. Although Roprostim can significantly reduce the risk of bleeding clinically, a variety of adverse reactions may still occur during use. The common adverse reactions are analyzed from several aspects below.
First of all, hematological reactions are one of the most common adverse reactions of loplastin. Because its effect directly stimulates megakaryocytes to produce platelets, some patients may experience platelet fluctuations in the early stages of treatment, with platelet counts being too high or too low. Although high platelet count (>400×10^9/L) rarely causes clinical symptoms, it carries a risk of thrombosis, so platelet levels need to be monitored regularly and the dosage adjusted appropriately. In addition, individual patients may have mild abnormalities in neutrophils or red blood cells, but these are generally rare.

Secondly, bone marrow-related reactions are also a concern for Roprostim. Long-term use of loplastin may lead to the development of myelofibrosis or myeloreticular fibrosis. Although clinical studies have shown that myelofibrosis is reversible in most patients and can be partially or completely recovered after discontinuation of the drug, for patients who rely on loplastin to maintain platelet levels for a long time, bone marrow morphological changes need to be regularly assessed through bone marrow aspiration. Although myelofibrosis is rare, clinical attention should be paid if it is accompanied by anemia, leukopenia, or abnormally elevated platelets.

Third, infections and immune system-related reactions are also common. Due to the inherent immune abnormalities of ITP patients and the fact that the use of roplastin may affect the bone marrow hematopoietic microenvironment, some patients develop symptoms such as upper respiratory tract infection, nasopharyngitis or mild fever during use. Most of these adverse reactions are mild to moderate and self-limiting, but it is necessary to pay attention to changes in the patient's immune status, handle them promptly, and prevent serious infections.
In addition, other adverse reactions include injection site reactions, headache, joint pain, and muscle pain. Roprostim is administered by subcutaneous injection. Mild pain, redness, swelling or itching may occur at the injection site, but this can generally be relieved without special treatment. Headache, joint or muscle pain occurs in some patients, is usually mild or moderate, and can be improved through symptomatic treatment without affecting continued medication.
Finally, it should be noted that the adverse reactions of roplastin are dose-dependent, and the principle of “starting with a low dose and gradually adjusting” should be followed in clinical use. Regular monitoring of platelet count, hemogram and bone marrow status is the key to preventing serious adverse reactions. At the same time, patients should maintain good living habits during treatment to avoid the risk of bleeding and infection. Based on comprehensive clinical trials and real-world data, the adverse reactions of Ropremilast are generally controllable, and the vast majority of patients can safely and effectively maintain platelet levels and achieve the treatment goal of reducing bleeding events.
To sum up, the common adverse reactions of Roprostim include platelet fluctuations, myelofibrosis, infection and immune-related symptoms, as well as injection site reactions and mild to moderate systemic symptoms. Through individualized dose adjustment, regular monitoring of blood and bone marrow indicators, and timely treatment of symptoms, the vast majority of patients can use loprostim within a safe and controllable range, significantly improving platelet levels and clinical prognosis.
Reference: https://www.drugs.com/